Cardio Diagnostics Holdings (NASDAQ: CDIO), an AI-powered precision cardiovascular medicine company, announced that Atlas Healthcare Physicians, an independent physician association serving managed care populations across Los Angeles and Orange counties, will provide coverage for the company’s Epi+Gen CHD and PrecisionCHD tests for eligible members with prior authorization. The coverage expands access to physician-ordered blood tests designed to assess coronary heart disease risk and support diagnosis and personalized treatment planning.
Cardio Diagnostics said Epi+Gen CHD evaluates a patient’s three-year risk of a coronary heart disease event, while PrecisionCHD helps diagnose coronary heart disease and identify its underlying molecular drivers. The company noted that both tests are noninvasive blood-based diagnostics that do not require fasting or radiation exposure, supporting broader adoption of precision cardiovascular medicine across community healthcare networks. This partnership with Atlas Healthcare Physicians marks a significant step in making advanced cardiovascular diagnostics more accessible to managed care populations in Southern California.
The announcement underscores the growing importance of precision medicine in cardiovascular disease management. By integrating AI-driven genetic and epigenetic analysis, Cardio Diagnostics aims to provide more personalized risk assessment and treatment options. The tests are designed to complement traditional risk factors, offering a more comprehensive view of a patient's coronary heart disease risk. The inclusion of these tests in Atlas Healthcare Physicians' coverage portfolio could lead to earlier detection and more tailored interventions for at-risk patients.
Cardio Diagnostics is an artificial intelligence-powered precision cardiovascular medicine company that makes cardiovascular disease prevention, detection, and management more accessible, personalized, and precise. The company was formed to further develop and commercialize clinical tests by leveraging a proprietary Artificial Intelligence-driven Integrated Genetic-Epigenetic Engine for cardiovascular disease.
For more information, visit the company's newsroom at https://nnw.fm/CDIO. The full press release can be viewed at https://nnw.fm/EFQen.
